These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 15362179)
21. How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis? Boonen A; van der Heijde D; Landewé R; van Tubergen A; Mielants H; Dougados M; van der Linden S Ann Rheum Dis; 2007 Jun; 66(6):771-7. PubMed ID: 17213254 [TBL] [Abstract][Full Text] [Related]
22. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Glasziou P; Alexander J; Beller E; Clarke P; Health Qual Life Outcomes; 2007 Apr; 5():21. PubMed ID: 17462100 [TBL] [Abstract][Full Text] [Related]
23. Validation of the EQ-5D in patients with a history of acute coronary syndrome. Ellis JJ; Eagle KA; Kline-Rogers EM; Erickson SR Curr Med Res Opin; 2005 Aug; 21(8):1209-16. PubMed ID: 16083530 [TBL] [Abstract][Full Text] [Related]
24. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850 [TBL] [Abstract][Full Text] [Related]
26. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F; Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822 [TBL] [Abstract][Full Text] [Related]
27. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE. Garcia-Gordillo MÁ; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellan-Perpiñan JM; Sanchez-Martinez FI Nutr Hosp; 2015 Dec; 32(6):2808-21. PubMed ID: 26667738 [TBL] [Abstract][Full Text] [Related]
28. Responsiveness of EQ-5D utility indices in alcohol-dependent patients. Günther OH; Roick C; Angermeyer MC; König HH Drug Alcohol Depend; 2008 Jan; 92(1-3):291-5. PubMed ID: 17888587 [TBL] [Abstract][Full Text] [Related]
29. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Griebsch I; Coast J; Brown J Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026 [TBL] [Abstract][Full Text] [Related]
30. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Bharmal M; Thomas J Value Health; 2006; 9(4):262-71. PubMed ID: 16903996 [TBL] [Abstract][Full Text] [Related]
31. Is there a difference between EQ-5D and SF-6D in the clinical setting? a comparative study on the quality of life measured by AIMS2-SF, EQ-5D and SF-6D scales for osteoarthritis patients. Zhang F; Yang Y; Huang T; Zhang Y; Zhao L; Li S Int J Rheum Dis; 2018 Jun; 21(6):1185-1192. PubMed ID: 27463704 [TBL] [Abstract][Full Text] [Related]
32. Unchained melody: revisiting the estimation of SF-6D values. Craig BM Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242 [TBL] [Abstract][Full Text] [Related]
33. Preference-based SF-6D scores derived from the SF-36 and SF-12 have different discriminative power in a population health survey. Luo N; Wang P; Fu AZ; Johnson JA; Coons SJ Med Care; 2012 Jul; 50(7):627-32. PubMed ID: 22456112 [TBL] [Abstract][Full Text] [Related]
34. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Pickard AS; Wilke C; Jung E; Patel S; Stavem K; Lee TA Respir Med; 2008 Apr; 102(4):519-36. PubMed ID: 18180151 [TBL] [Abstract][Full Text] [Related]
35. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population. Couzner L; Crotty M; Norman R; Ratcliffe J Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538 [TBL] [Abstract][Full Text] [Related]
36. Comparison of population health status in six european countries: results of a representative survey using the EQ-5D questionnaire. König HH; Bernert S; Angermeyer MC; Matschinger H; Martinez M; Vilagut G; Haro JM; de Girolamo G; de Graaf R; Kovess V; Alonso J; Med Care; 2009 Feb; 47(2):255-61. PubMed ID: 19169128 [TBL] [Abstract][Full Text] [Related]
37. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. van Stel HF; Buskens E Health Qual Life Outcomes; 2006 Mar; 4():20. PubMed ID: 16563170 [TBL] [Abstract][Full Text] [Related]
38. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort. Gaujoux-Viala C; Rat AC; Guillemin F; Flipo RM; Fardellone P; Bourgeois P; Fautrel B Ann Rheum Dis; 2012 Sep; 71(9):1478-83. PubMed ID: 22419775 [TBL] [Abstract][Full Text] [Related]
39. A comparison of individual and social time trade-off values for health states in the general population. Burström K; Johannesson M; Diderichsen F Health Policy; 2006 May; 76(3):359-70. PubMed ID: 16214258 [TBL] [Abstract][Full Text] [Related]
40. Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients. Luyten J; Marais C; Hens N; De Schrijver K; Beutels P Value Health; 2011; 14(2):282-90. PubMed ID: 21296602 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]